Dr. Heribert Bohlen MD
PhD Chief Executive Officer
is co-founder and CEO of Axiogenesis. At the University hospital in Cologne he led the department of Immunology and experimental Immunotherapy. He designed and finalized numerous experimental clinical studies with bispecifc antibodies and novel cellular vaccines.
During his clinical duties he was responsible for the bone marrow transplantation and was a member of thestiring group of the German Hodgkin Study group. As scientist at the Free University Brussels and The University of Cologne he achieved several awards and is the author of over 80 peer reviewed publications. He is responsible for Research and Development at Axiogenesis.
Dr. Bernd Fronhoff
Chief Financial Officer – Chief Operating Officer
is in charge of financial and operational affairs. He joined the company in 2001 and became shareholder in 2005. Before Axiogenesis, Bernd had been working in the TV- and Media-Industry covering Marketing, Sales and Corporate Management positions.